AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31546833 — intervention group
Group type: EXPERIMENTAL
Intervention: Scabies group (6628 patients)
Number of subjects: 33537
Study 31546833 — intervention group
Group type: COMPARATOR
Intervention: Control group (26,509 patients)
Number of subjects: 33537
Study 28590452 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein 54 mg/day
Number of subjects: 22
Study 28590452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 26052790 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily sensorimotor enrichment administered by parents along with standard care
Number of subjects: 0
Study 26052790 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 0
Study 26052790 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor enrichment therapy
Number of subjects: 0
Study 26052790 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset of sensory stimuli
Number of subjects: 0
Study 23487599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 23487599 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 U/d cholecalciferol
Number of subjects: 283
Study 23487599 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 U/d cholecalciferol
Number of subjects: 283
Study 23487599 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 U/d cholecalciferol
Number of subjects: 283
Study 23487599 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (each additional 1000 U/d)
Number of subjects: 283
Study 23487599 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma 25-hydroxyvitamin D increase (1-ng/mL)
Number of subjects: 283
Study 23487599 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation
Number of subjects: 283
Study 22039430 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose (4 mL 1% TFV gel)
Number of subjects: 49
Study 22039430 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose (QD or BID for 2 weeks)
Number of subjects: 49
Study 22039430 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose (MD)
Number of subjects: 49
Study 22039430 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose (SD)
Number of subjects: 49
Study 19451442 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 903
Study 19451442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 903
Study 19451442 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (after censoring placebo patients who crossed over)
Number of subjects: 903
Study 19451442 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after censoring patients who crossed over)
Number of subjects: 903
Study 16387891 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-elemental formula (Peptamen, 35 kcal/kg/d)
Number of subjects: 30
Study 16387891 — intervention group
Group type: COMPARATOR
Intervention: Polymeric formula (Sondalis-Iso, 35 kcal/kg/d)
Number of subjects: 30
Study 12816740 — intervention group
Group type: EXPERIMENTAL
Intervention: cilomilast, 15 mg two times a day
Number of subjects: 59
Study 12816740 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 59
Study 10370734 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral internal mammary artery bypass
Number of subjects: 73
Study 10370734 — intervention group
Group type: COMPARATOR
Intervention: Saphenous vein grafts only
Number of subjects: 73
Study 10370734 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of uni- or bilateral internal mammary artery(ies) with saphenous vein grafts
Number of subjects: 73
Study 8677206 — intervention group
Group type: COMPARATOR
Intervention: IDDM without diabetic nephropathy
Number of subjects: 12
Study 8677206 — intervention group
Group type: EXPERIMENTAL
Intervention: IDDM with diabetic nephropathy (conservatively treated)
Number of subjects: 12
Study 8677206 — intervention group
Group type: EXPERIMENTAL
Intervention: IDDM with end stage renal failure (haemodialysis)
Number of subjects: 12
Study 8677206 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic renal failure of non-diabetic origin
Number of subjects: 12
Study 8677206 — intervention group
Group type: EXPERIMENTAL
Intervention: End stage renal failure of non-diabetic origin (haemodialysis)
Number of subjects: 12
Study 1882375 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone (2 mg/kg)
Number of subjects: 20
Study 1882375 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 20
Study 1882375 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone (first bolus)
Number of subjects: 20
Study 1882375 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone (second bolus)
Number of subjects: 20
Study 6135440 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (24 h therapy)
Number of subjects: 0
Study 6135440 — intervention group
Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 0
Study 28183399 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐STEPS program (Motivational Interviewing and SR-skills training)
Number of subjects: 91
Study 28183399 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 91
Study 26799522 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL/MPS)
Number of subjects: 119
Study 26799522 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (TAC/MPS)
Number of subjects: 119
Study 24132979 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal high protein and energy supplementation
Number of subjects: 1459
Study 24132979 — intervention group
Group type: COMPARATOR
Intervention: Maternal supplementation during lactation
Number of subjects: 1459
Study 22285180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib 45 mg/day
Number of subjects: 71
Study 22285180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 19639458 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenaculum application to the cervix during IUI (Group 2, n=232)
Number of subjects: 468
Study 19639458 — intervention group
Group type: COMPARATOR
Intervention: No tenaculum application to the cervix during IUI (Group 1, n=236)
Number of subjects: 468
Study 17199725 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 70/30 (BIAsp 70/30)
Number of subjects: 0
Study 17199725 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study 16291982 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg
Number of subjects: 1036
Study 16291982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1036
Study 16291982 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 5 mg
Number of subjects: 1036
Study 12200523 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-allergic mattress covers
Number of subjects: 30
Study 12200523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9761503 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxalate-rich diet (1211 mg calcium/day)
Number of subjects: 14
Study 9761503 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and oxalate-rich diet (3858 mg calcium/day)
Number of subjects: 14
Study 9761503 — intervention group
Group type: COMPARATOR
Intervention: Free-choice diet
Number of subjects: 14
Study 9761503 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxalate-rich diet
Number of subjects: 14
Study 9761503 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and oxalate-rich diet
Number of subjects: 14
Study 7835212 — intervention group
Group type: COMPARATOR
Intervention: HLA‐A, ‐B, ‐C, ‐DR, and ‐DQ typing
Number of subjects: 50
Study 7835212 — intervention group
Group type: COMPARATOR
Intervention: HLA‐DR2, ‐DR5 and ‐DQ1
Number of subjects: 50
Study 7835212 — intervention group
Group type: COMPARATOR
Intervention: HLA haplotype analysis
Number of subjects: 50
Study 7835212 — intervention group
Group type: COMPARATOR
Intervention: HLA haplotypes A1,B17 and DR2,DQ1
Number of subjects: 50
Study 7835212 — intervention group
Group type: EXPERIMENTAL
Intervention: GLOI phenotype GLOI 2‐1
Number of subjects: 50
Study 2970855 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosenopril
Number of subjects: 11
Study 31856981 — intervention group
Group type: EXPERIMENTAL
Intervention: 4°C hypothermic perfusion
Number of subjects: 80
Study 31856981 — intervention group
Group type: COMPARATOR
Intervention: 24°C control
Number of subjects: 80
Study 28476288 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily (blinded phase)
Number of subjects: 10180
Study 28476288 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (non-blinded phase)
Number of subjects: 10180
Study 25720930 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 106
Study 25720930 — intervention group
Group type: COMPARATOR
Intervention: Surgical ligation with attempted stripping/excision
Number of subjects: 106
Study 23353641 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA (17‐23 mg/kg/day)
Number of subjects: 198
Study 23353641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 23353641 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA
Number of subjects: 198
Study 23353641 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both UDCA and placebo)
Number of subjects: 198
Study 20219315 — intervention group
Group type: EXPERIMENTAL
Intervention: Training focused on patient-centered communication about behavioral risk factors
Number of subjects: 28
Study 20219315 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 28
Study 19081408 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 0.5 mg/kg
Number of subjects: 659
Study 19081408 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 0.75 mg/kg
Number of subjects: 659
Study 19081408 — intervention group
Group type: COMPARATOR
Intervention: UFH (activated clotting time‐adjusted)
Number of subjects: 659
Study 17494925 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-6/11/16/18 vaccine
Number of subjects: 10565
Study 17494925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10565
Study 17494925 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 10565
Study 15508985 — intervention group
Group type: EXPERIMENTAL
Intervention: Splinted implants
Number of subjects: 36
Study 15508985 — intervention group
Group type: COMPARATOR
Intervention: Unsplinted implants
Number of subjects: 36
Study 11677200 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous etanercept 25 mg twice weekly
Number of subjects: 43
Study 11677200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 9155608 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning
Number of subjects: 33
Study 9155608 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 7957014 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mg nicotine gum
Number of subjects: 691
Study 3116695 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified TPN (15% dextrose, fat, and 5% amino acids)
Number of subjects: 88
Study 3116695 — intervention group
Group type: COMPARATOR
Intervention: Conventional TPN (25% dextrose and 4.25% amino acids)
Number of subjects: 88
Study 3116695 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TPN regimens
Number of subjects: 88
Study 2694612 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildronate
Number of subjects: 50
Study 2694612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31879945 — intervention group
Group type: EXPERIMENTAL
Intervention: Pixantrone + rituximab (PIX + R)
Number of subjects: 312
Study 31879945 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine + rituximab (GEM + R)
Number of subjects: 312
Study 30904703 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanolic extract of Alchemilla vulgaris
Number of subjects: 0
Study 30904703 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel with propyleneglycolic extract
Number of subjects: 0
Study 30904703 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogels with A. vulgaris extracts
Number of subjects: 0
Study 28767558 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 66
Study 28767558 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 66
Study 25821958 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumboperitoneal shunting
Number of subjects: 32
Study 23765713 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary plus prophylactic upper neck irradiation (UNI)
Number of subjects: 301
Study 23765713 — intervention group
Group type: COMPARATOR
Intervention: Primary plus whole-neck irradiation (WNI)
Number of subjects: 301
Study 21106207 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 174
Study 21106207 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 174
Study 21106207 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 174
Study 21106207 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherent patients
Number of subjects: 174
Study 21106207 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adherent patients
Number of subjects: 174
Study 19961001 — intervention group
Group type: EXPERIMENTAL
Intervention: Meteospazmil
Number of subjects: 0
Study 17405171 — intervention group
Group type: EXPERIMENTAL
Intervention: 23G needle
Number of subjects: 100
Study 17405171 — intervention group
Group type: COMPARATOR
Intervention: 21G needle
Number of subjects: 100
Study 17405171 — intervention group
Group type: EXPERIMENTAL
Intervention: Both needles
Number of subjects: 100
Study 15304381 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 422
Study 15304381 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 422
Study 11331640 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin acetate (3.6 mg/month for 6 months)
Number of subjects: 47
Study 11331640 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (MPA; 30 mg/day for 6 months)
Number of subjects: 47
Study 9013162 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose midazolam (35 micrograms/kg) and pethidine (700 micrograms/kg in 48 patients, 500 micrograms/kg in 102 patients)
Number of subjects: 150
Study 9013162 — intervention group
Group type: COMPARATOR
Intervention: Midazolam and placebo pethidine
Number of subjects: 150
Study 9013162 — intervention group
Group type: COMPARATOR
Intervention: Pethidine and placebo midazolam
Number of subjects: 150
Study 7700028 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 108
Study 7700028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 2975995 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) 15 pmol kg‐1 min‐1
Number of subjects: 9
Study 2975995 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP) 0.003 pmol kg‐1 min‐1
Number of subjects: 9
Study 2975995 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP + ANF
Number of subjects: 9
Study 2975995 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 9
Study 2975995 — intervention group
Group type: COMPARATOR
Intervention: P + P
Number of subjects: 9
Study 2975995 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP + P
Number of subjects: 9
Study 30106888 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-randomized weak coherent states with different mean photon numbers
Number of subjects: 0
Study 26785249 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention delivered over 20 weeks
Number of subjects: 325
Study 26785249 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 325
Study 26785249 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 325
Study 23340794 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of sodium restriction on habitual diet (Group A)
Number of subjects: 39
Study 23340794 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 39
Study 22438530 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-month dual-antiplatelet therapy (clopidogrel + aspirin)
Number of subjects: 2013
Study 22438530 — intervention group
Group type: COMPARATOR
Intervention: 6-month dual-antiplatelet therapy (clopidogrel + aspirin)
Number of subjects: 2013
Study 20536600 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg twice daily
Number of subjects: 880
Study 20536600 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 50 mg twice daily
Number of subjects: 880
Study 17087998 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 60
Study 17087998 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 60
Study 17087998 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 60
Study 15502893 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural treatment of chronic tinnitus
Number of subjects: 125
Study 15502893 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rating instrument for SoC
Number of subjects: 125
Study 14736356 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-needle acupuncture at Chengjiang (midline between lower lip and chin)
Number of subjects: 41
Study 14736356 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture at a superficial point (tip of the chin)
Number of subjects: 41
Study 14736356 — intervention group
Group type: COMPARATOR
Intervention: No acupuncture
Number of subjects: 41
Study 10618937 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 75
Study 10618937 — intervention group
Group type: COMPARATOR
Intervention: Tramadol 50 mg
Number of subjects: 75
Study 10618937 — intervention group
Group type: COMPARATOR
Intervention: Tramadol 75 mg
Number of subjects: 75
Study 8951985 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch (0 mg) during abstinence
Number of subjects: 0
Study 8951985 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches (10 mg, 20 mg, 30 mg)
Number of subjects: 0
Study 8951985 — intervention group
Group type: COMPARATOR
Intervention: Nicotine abstinence (0 mg patch)
Number of subjects: 0
Study 1673577 — intervention group
Group type: EXPERIMENTAL
Intervention: Bopindolol (a beta-blocker with a slightly expressed ISA)
Number of subjects: 86
Study 1673577 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (cardioselective beta-blocker)
Number of subjects: 86
Study 1673577 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 86
Study 7074402 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.30 mg/kg)
Number of subjects: 48
Study 7074402 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone (3.99 mg/kg)
Number of subjects: 48
Study 7074402 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone with diazepam premedication
Number of subjects: 48
Study 7074402 — intervention group
Group type: COMPARATOR
Intervention: Midazolam with diazepam premedication
Number of subjects: 48
Study 29514030 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 331
Study 29514030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study 27076599 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 0
Study 27076599 — intervention group
Group type: COMPARATOR
Intervention: Intravenous alteplase administration (drip and ship)
Number of subjects: 0
Study 27076599 — intervention group
Group type: COMPARATOR
Intervention: Presentation during work hours
Number of subjects: 0
Study 27076599 — intervention group
Group type: COMPARATOR
Intervention: Drip-ship transfer
Number of subjects: 0
Study 27076599 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 0
Study 27076599 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon guide catheter use
Number of subjects: 0
Study 24577626 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 15 mg once weekly and PLD 40 mg/m(2) once every 4 weeks
Number of subjects: 19
Study 22720738 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised cooled dialysate (set at 0.5°C less than the patient's own temperature, up to a maximum of 36°C)
Number of subjects: 73
Study 22720738 — intervention group
Group type: COMPARATOR
Intervention: Conventional dialysate temperature of 37°C
Number of subjects: 73
Study 22720738 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised cooled dialysate
Number of subjects: 73
Study 21058483 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 63
Study 21058483 — intervention group
Group type: COMPARATOR
Intervention: Simple acupuncture
Number of subjects: 63
Study 17937357 — intervention group
Group type: EXPERIMENTAL
Intervention: BOOT Camp Survival Training for Navy Recruits‐A Prescription (BOOT STRAP)
Number of subjects: 1199
Study 17937357 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1199
Study 17937357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost analysis
Number of subjects: 1199
Study 15809829 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium phosphate cement (CPC)
Number of subjects: 12
Study 15809829 — intervention group
Group type: COMPARATOR
Intervention: Polymethylmethacrylate (PMMA)
Number of subjects: 12
Study 12465157 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (500 IU)
Number of subjects: 136
Study 12465157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 9468424 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (5.3±1.1 mg)
Number of subjects: 200
Study 9468424 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (11.2±2.3 mg)
Number of subjects: 200
Study 9468424 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.2 mg)
Number of subjects: 200
Study 8540665 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone catheter (23G, 15 cm long)
Number of subjects: 79
Study 8540665 — intervention group
Group type: COMPARATOR
Intervention: Teflon cannula (18G, 4.4 cm long)
Number of subjects: 79
Study 2092025 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg nocte
Number of subjects: 76